All posts by bioadc

The Success of Seattle Genetics/Wutian ADC Adcetris for Phase III Clinical Surgery of Peripheral T Cell Lymphoma (PTCL)

October 03, 2018 – Seattle Genetics and Takeda recently announced the evaluation of antibody conjugates Adcetris (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma (PTCL, also known as mature Phase IIIRead More…

antibody drug conjugates

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…